At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 21 enrolled
Drug / intervention
SGI-110drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
In Brief
A Phase 1 clinical trial evaluating SGI-110 for Acute Myeloid Leukemia. Completed, enrolled 21 participants across 3 sites.
Detailed Summary
To evaluate the tolerability and pharmacokinetics of SGI-110 when administered subcutaneously to Japanese patients with acute myeloid leukemia (AML).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartJan 2015
Primary CompletionJun 2017
Study CompletionMay 2019
TodayJul 2026
First PostedNov 19, 2014
Enrollment StartJan 7, 2015
Primary CompletionJun 14, 2017
Study CompletionMay 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.6 years ago
Interventions
SGI-110drug